141 results about "Ribonucleoside" patented technology

One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety.

The present invention relates to a method for synthesizing an RNA molecule of a given sequence, comprising the step of determining the fraction (1) for each of the four nucleotides G, A, C and U in said RNA molecule, and the step of synthesizing said RNA molecule by in vitro transcription in a sequence-optimized reaction mix, wherein said sequence-optimized reaction mix comprises the four ribonucleoside triphosphates GTP, ATP, CTP and UTP, wherein the fraction (2) of each of the four ribonucleoside triphosphates in the sequence-optimized reaction mix corresponds to the fraction (1) of the respective nucleotide in said RNA molecule, a buffer, a DNA template, and an RNA polymerase. Further, the present invention relates to a bioreactor (1) for synthesizing RNA molecules of a given sequence, the bioreactor (1) having a reaction module (2) for carrying out in vitro RNA transcription reactions in a sequence-optimized reaction mix, a capture module (3) for temporarily capturing the transcribed RNA molecules, and a control module (4) for controlling the infeed of components of the sequence-optimized reaction mix into the reaction module (2), wherein the reaction module (2) comprises a filtration membrane (21) for separating nucleotides from the reaction mix, and the control of the infeed of components of the sequence-optimized reaction mix by the control module (4) is based on a measured concentration of separated nucleotides.

The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having an alternating motif and another strand having a hemimer motif, a blockmer motif, a fully modified motif or a positionally modified motif. At least one of the strands has complementarity to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.

A method for preparing a phosphorothioate RNA based on the oxazaphospholidine method, wherein cyanoethoxymethyl group is used instead of tert-butyldimethylsilyl group as a protective group of 2′-hydroxyl group of RNA.

The invention provides a recombinant microorganism for producing cytidine and a method for producing the cytidine from the recombinant microorganism. A degradation and use gene of the cytidine is knocked off, and the gene encodes cytidine ammonialyase, ribonucleotide hydrolase, cytidine/uridine kinase and nucleoside transporter. Meanwhile key enzymes in biological synthesis process of the cytidine are over-expressed, including degrading cytidine triphosphoric acid to cytidine triphosphoric acid pyrophosphorylase of the cytidine monohosphoric acid, and catalyzing the cytidine monohosphoric acid to cytidine monohosphoric acid phosphorylase of the cytidine. In addition, pyrimidine nucleoside process is subjected to genetic engineering reform, and feedback inhibition of the synthesis process is relieved. By using a biological fermentation method, the cytidine yield greater than 20g/L can be achieved for a recombinant strain in a fermentation tank of 5L, industrial on-scale production can be achieved, and meanwhile the recombinant microorganism is low in cytidine production cost, small in pollution, green and environmental-friendly and relatively high in popularization and application value.

The invention discloses an isothermal nucleic acid amplification reaction reagent which comprises Tris buffer solutions, potassium acetate, magnesium acetate, dithiothreitol, polyethylene glycol, adenosine triphosphate (ATP), deoxy-ribonucleoside triphosphate (dNTPs), phosphocreatine, creatine kinase, a primer group, single-strand binding (SSD) protein, colon bacillus helicase RecQ protein, UvsY protein and DNA polymerase. The invention further discloses an isothermal nucleic acid amplification method which includes steps of extracting DNA or performing inverse transcription after DNA extracting, and adding the isothermal nucleic acid amplification reaction reagent and reacting the mixture at a temperature in a range between 25 DEG C and 45 DEG C for 10 minutes to 60 minutes to complete the nucleic acid amplification. Compared with traditional polymerase chain reaction (PCR) technologies and according to the technology, nearly no professional instrument is needed, the operation is simple, technical requirements for operators are low, and the reaction time only needs about half an hour.

The invention discloses a quadruple fluorescent PCR (Polymerase Chain Reaction) detection kit for common chicken food-borne bacteria and an application method thereof. The kit contains a fluorescent PCR solution and standards of Clostridium perfringens, Salmonella enteritidis, Escherichia coli O157: H7 and Campylobacter jejuni, wherein the fluorescent PCR solution contains Taq DNA (deoxyribonucleic acid) polymerase, a PCR buffer solution, Mg<2+>, dNTPs (deoxy-ribonucleoside triphosphates), four pairs of bacterial specific primers and four kinds of corresponding fluorescent probes. According to the detection kit and the application method thereof, four kinds of chicken-carried main food-borne pathogenic bacteria, namely Clostridium perfringens, Salmonella enteritidis, Escherichia coli O157: H7 and Campylobacter jejuni, can be rapidly and accurately detected by using quadruple fluorescent PCR, and the detection kit can be applied to the assay of bacteria, the diagnosis of diseases and epidemiological investigation.

Complexes of antibiotics and metals are provided that are useful in detecting microorganisms, including gram-positive bacteria, Mycobacteria, permeabilized gram-negative bacteria, protozoans and other biological analytes, and are particularly useful in detecting gram-positive bacteria. The complexes are preferably chelated complexes wherein the antibiotic is a glycopeptide antibiotic, quinolone antibiotic, ribonucleoside antibiotic, mixtures thereof, and analogs and derivatives thereof, and (b) a detectable label comprising a transition or lanthanide metal. The complexes provide for chemiluminescent, fluorescent or magnetic detection of the analyte. Methods of synthesizing and using the complexes are also provided.

This invention relates to nucleoside, nucleotide, and oligonucleotide analogs that incorporate non-standard nucleobase analogs, defined to be those that present a pattern of hydrogen bonds to a paired nucleobase analog in a complementary strand that is different from the pattern presented by adenine, guanine, cytosine, and thymine. The invention is specifically concerned with nucleotide analogs that present the donor-donor-acceptor, hydrogen bonding patterns on pyrimidine analogs, and especially those that are analogs of ribonucleotides, including protected ribonucleotides suitable for phosphoramidite-based synthesis of RNA. The heterocycles on these nucleoside analogs are aminopyridones that have electron withdrawing groups attached to the position analogous to the 5-position of the ring in standard pyrimidines, including nitro, cyano, and carboxylic acid derivatives.

The invention relates to a preparation method of an oxidation coenzyme I. According to the method, nicotinamide ribonucleoside (NR) and adenosine disodium triphosphate (ATP-Na2) react with each other to obtain the oxidation coenzyme I (NAD+, Nicotinamide Adenine Dinucleotide+) in a buffer solution with the pH of 5.0 to 8.0 at a temperature of 30 DEG C to 40 DEG C under the catalytic action of nicotinamide ribonucleoside kinase (NRK) under the condition of the existence of divalent metal ions. According to the invention, a biocatalysis method is adopted, the oxidation coenzyme is prepared by utilizing an NRK one pot process, the reaction system is simple, the conditions are mild, and the preparation method has wide industrialization application prospect.

The invention belongs to the field of biological products, and relates to a detection kit and a detection method for rapidly detecting salmonella by utilizing an LAMP (loop-mediated isothermal amplification) technique. The kit is composed of a salmonella genome extracting reagent and an LAMP reaction reagent, wherein the salmonella genome extracting reagent comprises the following components: SDS (sodium dodecyl sulfate), protease K, CTAB (cetyltrimethyl ammonium bromide)/NaCl solution and NaAC; and the LAMP reaction reagent is composed of a reaction liquid A and a reaction liquid B, the reaction liquid A comprises the following components: 10*Lampbuffer, Bst DNA (deoxyribonucleic acid) polymerase, dNTP (deoxy-ribonucleoside triphosphate), an interprimer 1, an interprimer 2, an outer primer 1, an outer primer 2, lycine and ultrapure water, and the reaction liquid B is a fluorescent dye. The invention can be used to carry out LAMP detection on salmonella, has the characteristics of rapid detection, high accuracy, high sensitivity and convenient field application, and can be widely applied in the fields of veterinarian, food and exit-entry quarantine, etc.

The invention relates to a hypertension gene polymorphism fluorescent PCR solubility curve detecting kit and application thereof, and a hypertension medication gene multiple-PCR solubility curve detecting method. The hypertension gene polymorphism fluorescent PCR solubility curve detecting kit mainly comprises a primer combination, a probe combination, and PCR reaction agents such thermally activated polymerases, PCR buffer solution and dNTPs (deoxy-ribonucleoside triphosphates) and involves polymorphism detection of 7 hypertension-related genes including CYP2D6*10, CYP2C9*3, ADRB1(1165G)C), AGTR1(1166A)C), CYP3A5*3, NPPA(T2338C) and ACE(I/D); the three reaction agents are applied to perform PCR amplification and solubility analysis to determine the related polymorphism of the 7 genes to guide clinical customized application of 5 majors types of hypertension drugs. The hypertension gene polymorphism fluorescent PCR solubility curve detecting kit can easily complete detection through 3reaction tubes, and meanwhile, save a nucleic acid extraction process, simplify operation steps and achieve a simple interpretation method.

The present invention relates to an agent containing L-arginine, 0.2 to 20 parts by weight of L-ascorbic acid per 1 part by weight of L-arginine, and, if desired, at least one selected from the group consisting of ribonucleic acids, ribonucleotides and ribonucleosides. The agent can treat mitochondrial disease which shows a variety of symptoms caused by dysfunction of mitochondria in cells. L-arginine contained in the agent for treating mitochondrial disease of the present invention increases an NO radical level to thereby dilate the arteries. L-ascorbic acid serves to mitigate a harsh taste and acrid feeling accompanied with the intake of L-arginine and eliminate excessive NO radicals.

PCT No. PCT/JP95/02254 Sec. 371 Date May 5, 1997 Sec. 102(e) Date May 5, 1997 PCT Filed Nov. 6, 1995 PCT Pub. No. WO96/14434 PCT Pub. Date May 17, 1996Disclosed is a method for determining a nucleotide sequence of DNA product amplified by polymerase chain reaction not requiring removal of primers and/or 2'-deoxyribonucleoside-5'-triphosphates and/or derivatives thereof, which comprises reacting ribonucleoside-5'-triphosphates comprising ATP, GTP, CTP, UTP and derivatives thereof and one or more of 3'-deoxyribonucleotide-5'-triphosphates comprising 3'-dATP, 3'-dGTP, 3'-dCTP, 3'-dUTP and derivatives thereof in the presence of an RNA polymerase and a DNA product which has been amplified by polymerase chain reaction and contains a promoter sequence for the RNA polymerase to afford a nucleic acid transcription product, separating the obtained nucleic acid transcription product and determining a nucleic acid sequence from the resluting separated fractions.

The present invention is directed to the identification and use of ribonucleoside analogs to induce the mutation of an RNA virus, including BVDV, HIV and HCV, or a virus which otherwise replicates through an RNA intermediate. The increase in the mutation rate of the virus results in reduced viability of progeny generations of the virus, thereby inhibiting viral replication. In addition to these methods and related compositions, the invention provides methods and combinatorial chemistry libraries for screening ribonucleoside analogs for mutagenic potential.